Afficher la notice abrégée

TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials

dc.rights.licenseopenen_US
dc.contributor.authorITALIANO, Antoine
dc.contributor.authorBELCAID, L.
dc.contributor.authorCOUSIN, S.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTRIN, Kilian
dc.contributor.authorBAYLE, A.
dc.contributor.authorSOUBEYRAN, Isabelle
dc.contributor.authorALAME, M.
dc.contributor.authorBLOUIN, L.
dc.contributor.authorROULEAU, E.
dc.contributor.authorLACROIX, L.
dc.contributor.authorVASSEUR, D.
dc.contributor.authorBELLERA, Carine
dc.date.accessioned2024-01-22T11:18:13Z
dc.date.available2024-01-22T11:18:13Z
dc.date.issued2023-10
dc.date.conference2023-10-20
dc.identifier.issn0923-7534en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/187368
dc.description.abstractEnBackground Typical entry criteria in early phase studies include expected life expectancy greater than 3 months. However, this evaluation is quite subjective and more objective and reproducible tools are needed to improve patient selection for phase I trials. The quantification of ctDNA shed by measuring tumor fraction (TF) has been associated with prognosis in patients with solid tumors. Our objective was to develop and validate a nomogram integrating TF to predict overall survival in cancer patients referred for early phase studies. Methods All consecutive adult patients with an advanced solid tumor included between December 2020 and December 2021 in two precision medicine studies (BIP, NCT02534649, sponsor: Institut Bergonié, Bordeaux, France) and STING (NCT04932525, sponsor: Institut Gustave Roussy, Villejuif, France). All patients underwent comprehensive genomic profiling with the 324-gene FoundationOne®. TF was analyzed as a binary variable, indicating whether a specimen had TF ≥10% or TF <10%. Other variables included previously validated prognostic scores such as the Royal Marsden (RMHs: albumin, LDH, number of metastatic sites ) and the GRIm (LDH, neutrophil/lymphocyte ratio, albumin) scores as well as their individual components. Results TF > 10, the GRIM score and the RMH score were independent prognostic factors in the training dataset (BIP study n= 965 patients). We generated a nomogram based on TF, number of metastatic sites, albumine level and neutrophil/lymphocyte ratio. To determine the clinical usefulness of our nomogram, we compared it with the RMH and GRIM scores. For our nomogram, the area under the receiver operating characteristic curve (AUC) was 0.79 as compared with 0.65 and 0.68 for the RMH and GRIM scores respectively. In the validation dataset (STING study, n= 947), the AUC was 0.76 as compared with 0.60 and 0.64 for for the RMH and GRIM scores respectively. The nomogram was well-calibrated in both the training and validation datasets. Conclusions This is the first prospective analysis confirming that TF is a strong prognostic factor in patients with advanced solid tumors. The TIMES nomogram represent an helpful tool in the process of patient selection for phase I trial entry.
dc.language.isoENen_US
dc.title.enTIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
dc.typeCommunication dans un congrèsen_US
dc.identifier.doi10.1016/j.annonc.2023.09.1891en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.pageS489-S489en_US
bordeaux.volume34en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issuesupplement 2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.conference.titleESMO Congress 2023en_US
bordeaux.countryesen_US
bordeaux.title.proceedingAbstract Book of the ESMO Congress 2023, 20 - 24 October 2023en_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.conference.cityMadriden_US
hal.identifierhal-04409421
hal.version1
hal.date.transferred2024-01-22T11:18:15Z
hal.invitedouien_US
hal.proceedingsouien_US
hal.conference.end2023-10-24
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.date=2023-10&amp;rft.volume=34&amp;rft.issue=supplement%202&amp;rft.spage=S489-S489&amp;rft.epage=S489-S489&amp;rft.eissn=0923-7534&amp;rft.issn=0923-7534&amp;rft.au=ITALIANO,%20Antoine&amp;BELCAID,%20L.&amp;COUSIN,%20S.&amp;TRIN,%20Kilian&amp;BAYLE,%20A.&amp;rft.genre=unknown


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée